SCHIZOPHRENIA
A phase 3 study to evaluate weight gain of ALKS 3831 compared to Olanzapine in adults with schizophrenia
Alermes, Inc
PI: Joseph McEvoy, M.D. A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/duinidine sulfate [Q]) as an adjunctive treatment for patients with residual schizophrenia. A randomized controlled trial of adjunctive tocilizumab in schizophrenia. NARSAD Independent Investigator Grant
PI: Brian Miller, M.D., Ph.D., MPH
A randomized controlled trial of adjunctive siltuximab in schizophrenia. Stanley Medical Research Institute
PI: Brian Miller, M.D., Ph.D., MPH
A potential state and relapse predictive marker in schizophrenia. National Institute of Mental Health
PI: Brian Miller, M.D., Ph.D., MPH
BDNF/TrkB: a possible therapeutic target for schizophrenia. National Institute of Mental Health
PI: Anilkumar Pillai, Ph.D
Paliperidone, mimicking paliperidone palmitate administration on brain BDNF: implications for relapse and neuroplasticity in schizophrenia. Ortho Mc-Neil Janssen Pharma
PI: Anilkumar Pillai, Ph.D
A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early intervention in patients with attenuated psychosis syndrome. Improving cognition via exercise in schizophrenia
National Institute of Mental Health (NIMH)
PI: Joseph McEvoy, M.D. Metformin and Lorcaserin for weight loss in people with schizophrenia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
PI: Joseph McEvoy, M.D. A phase II, 12-week, randomized, double-blind, placebo-controlled, parallel study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the three dose levels of TAK-831 in adjunctive treatment of adult patients with negative symptoms of schizophrenia
Millennium Pharmaceuticals, Inc. Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate the safety and efficacy of BIIB104 in subjects with cognitive impairment associated with schizophrenia
Biogen MA, Inc.